TGAP protocol

chemotherapy protocol consisting of above cpds, reverses cytosine arabinoside resistance in human leukemia lines lacking or expressing p53 protein

Networked: 0 relevant articles (0 outcomes, 0 trials/studies)

Therapy Context: Research Results

Therapeutics: 1158551
- Drug Therapy: 293145
  - Combination Drug Therapy: 12066
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - TGAP protocol
  - Antineoplastic Protocols: 55
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - TGAP protocol
- Clinical Protocols
  - Antineoplastic Protocols: 55
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - TGAP protocol
Enzymes and Coenzymes: 1
- Enzymes: 152586
  - Hydrolases: 2166
    - Amidohydrolases: 43
      - Asparaginase: 2285
        TGAP protocol
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - Pyrimidine Nucleosides: 50
      - Cytidine: 535
        Cytarabine: 6662
        TGAP protocol
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Purines: 651
      - Thioguanine: 835
        TGAP protocol
Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleosides: 6847
  - Pyrimidine Nucleosides: 50
    - Cytidine: 535
      - Cytarabine: 6662
        TGAP protocol
  - Arabinonucleosides: 1
    - Cytarabine: 6662
      - TGAP protocol
Organic Chemicals: 133
- Alcohols: 595
  - Glycols: 38
    - Ethylene Glycols: 8
      - Polyethylene Glycols: 3865
        TGAP protocol
Macromolecular Substances: 97
- Polymers: 13051
  - Polyethylene Glycols: 3865
    - TGAP protocol
Biomedical and Dental Materials
- Polymers: 13051
  - Polyethylene Glycols: 3865
    - TGAP protocol
Technology, Industry, and Agriculture
- Manufactured Materials
  - Biomedical and Dental Materials
    - Polymers: 13051
      - Polyethylene Glycols: 3865
        TGAP protocol